Bile acid receptors as targets for the treatment of dyslipidemia and cardiovascular disease

Journal of Lipid Research

Janne Prawitt¹  Bart Staels²  Barbara Gross³  Geoffrey Porez⁴ 

[1] Institut national de la santé et la recherche médicale (INSERM);;Université Droit &Université Lille Nord de France, U1011, F-59000 Lille, France;Université Lille Nord de France, F-59000 Lille, France;

关键词: atherosclerosis;    FXR;    glucose metabolism;    lipid metabolism;    TGR5;   

DOI  :  

来源: DOAJ

【 摘 要 】

Dyslipidemia is an important risk factor for cardiovascular disease (CVD) and atherosclerosis. When dyslipidemia coincides with other metabolic disorders such as obesity, hypertension, and glucose intolerance, defined as the metabolic syndrome (MS), individuals present an elevated risk to develop type 2 diabetes (T2D) as well as CVD. Because the MS epidemic represents a growing public health problem worldwide, the development of therapies remains a major challenge. Alterations of bile acid pool regulation in T2D have revealed a link between bile acid and metabolic homeostasis. The bile acid receptors farnesoid X receptor (FXR) and TGR5 both regulate lipid, glucose, and energy metabolism, rendering them potential pharmacological targets for MS therapy. This review discusses the mechanisms of metabolic regulation by FXR and TGR5 and the utility relevance of natural and synthetic modulators of FXR and TGR5 activity, including bile acid sequestrants, in the treatment of the MS.

【 授权许可】

Unknown